You are here

Merck

Merck gains U.S. patent office support in Keytruda dispute

MSN/Seeking Alpha

Wed, 06/4/25 - 10:46 pm

Halozyme Therapeutics

Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT

Fierce Biotech

Tue, 06/3/25 - 11:41 am

MoonLake Immunotherapeutics

ASCO25: Trodelvy and Keytruda to become new standard of care for frontline TNBC

Clinical Trials Arena

Mon, 06/2/25 - 11:24 pm

Gilead Sciences

triple negative breast cancer

#ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer

BioSpace

Fri, 05/30/25 - 11:49 am

Evopoint Biosciences

Summit Therapeutics

Merck plays lion tamer, taking middle dose of ROR ADC forward in relapsed or refractory DLBCL

Fierce Biotech

Fri, 05/30/25 - 11:39 am

zilovertamab vedotin

relapsed or refractory diffuse large B cell lymphoma

Merck and Daiichi Sankyo pull HER3-DXd's FDA filing

Pharmaphorum

Thu, 05/29/25 - 10:33 am

patritumab deruxtecan

Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change

Pharma Voice

Tue, 05/27/25 - 11:10 am

pharma industry

Merck KGaA shares data justifying pushing lupus drug into phase 3—despite recent setback

Fierce Biotech

Wed, 05/21/25 - 10:21 pm

clinical trials

Merck's Keytruda finds a path in ovarian cancer with phase 3 win in certain recurrent patients

Fierce Pharma

Thu, 05/15/25 - 10:25 pm

clinical trials

Merck begins construction on $1B Keytruda manufacturing facility in Delaware

Fierce Pharma

Wed, 04/30/25 - 10:54 am

drug manufacturing

Perioperative Keytruda Cuts Risk of Negative Events by Over 25% in Head and Neck Cancer

BioSpace

Mon, 04/28/25 - 09:38 am

head and neck cancer

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Fierce Pharma

Thu, 04/24/25 - 09:17 pm

Merck lowers profit outlook, partly due to $200 million expected tariff hit

CNBC

Thu, 04/24/25 - 10:51 am

Trodelvy-Keytruda combo improves cancer trial outcomes

Investing.com

Mon, 04/21/25 - 11:11 am

Gilead Sciences

metastatic triple-negative breast cancer

Merck inks $493M biobucks deal to use Cyprumed's tech to create oral peptides

Fierce Biotech

Tue, 04/15/25 - 07:40 pm

The 5 largest biopharma layoffs of Q1 2025

BioSpace

Fri, 04/11/25 - 11:47 am

Bristol Myers Squibb

Gilead Sciences

Merck granted Rob Davis a pay boost to $23.2M, inching CEO’s 2024 compensation closer to large pharma peers

Fierce Pharma

Thu, 04/10/25 - 10:04 pm

executive compensation

Five Biggest Drug Face-Offs in Pharma History

BioSpace

Wed, 04/9/25 - 11:38 am

Bristol Myers Squibb

The top 10 pharma R&D budgets for 2024

Fierce Biotech

Fri, 04/4/25 - 11:30 am

Bristol Myers Squibb

Merck's Winrevair slashes mortality-morbidity risk by 76%

Fierce Pharma

Mon, 03/31/25 - 11:02 am

clinical trials

Pages